Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Pathogenesis of the hypercoagulable state associated with malignancy

Kenneth A Bauer, MD
Section Editor
Lawrence LK Leung, MD
Deputy Editor
Jennifer S Tirnauer, MD


Many patients with cancer are in a hypercoagulable state. The spectrum of manifestations ranges from abnormal coagulation tests in the absence of thrombotic symptoms to massive thromboembolism.

This topic review will discuss the pathogenetic factors that might contribute to the hypercoagulable syndromes that can be associated with malignancy [1]. The contributions of chemotherapeutic drugs to the hypercoagulable state are discussed separately. (See "Drug-induced thrombosis in patients with malignancy".)

The prevention and treatment of hypercoagulable disorders associated with malignancy are discussed separately. (See "Risk and prevention of venous thromboembolism in adults with cancer" and "Treatment of venous thromboembolism in patients with malignancy", section on 'Therapy in special populations' and "Nonbacterial thrombotic endocarditis" and "Drug-induced thrombosis in patients with malignancy".)


The pathogenesis of the hypercoagulable state of malignancy involves the interplay of multiple variables. As an example, intact tumor cells may express procoagulant activity that can directly induce thrombin generation; in addition, normal host tissues may express procoagulant activity in response to the tumor. Comorbid factors such as bed rest, infection, surgery, and drugs, may play a contributory role and may determine whether an asymptomatic increase in coagulability becomes manifest clinically [2,3]. (See "Drug-induced thrombosis in patients with malignancy" and "Overview of the causes of venous thrombosis", section on 'Virchow's triad' and "Overview of the causes of venous thrombosis", section on 'Malignancy' and "Risk and prevention of venous thromboembolism in adults with cancer".)

Thrombotic episodes may precede the diagnosis of malignancy by months or years (see "Overview of the causes of venous thrombosis", section on 'Malignancy') and can present in one of the following ways [4]:

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Oct 23, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Dipasco PJ, Misra S, Koniaris LG, Moffat FL Jr. Thrombophilic state in cancer, part I: biology, incidence, and risk factors. J Surg Oncol 2011; 104:316.
  2. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6:401.
  3. Young A, Chapman O, Connor C, et al. Thrombosis and cancer. Nat Rev Clin Oncol 2012; 9:437.
  4. Levine M. Treatment of thrombotic disorders in cancer patients. Haemostasis 1997; 27 Suppl 1:38.
  5. Amico L, Caplan LR, Thomas C. Cerebrovascular complications of mucinous cancers. Neurology 1989; 39:522.
  6. Pinzon R, Drewinko B, Trujillo JM, et al. Pancreatic carcinoma and Trousseau's syndrome: experience at a large cancer center. J Clin Oncol 1986; 4:509.
  7. Edwards RL, Morgan DL, Rickles FR. Animal tumor procoagulants: registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis. Thromb Haemost 1990; 63:133.
  8. Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91:3093.
  9. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62:14.
  10. Rao LV. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992; 11:249.
  11. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992; 70:1194.
  12. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105:1734.
  13. Uno K, Homma S, Satoh T, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 2007; 96:290.
  14. Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6:1983.
  15. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27:4834.
  16. Yokota N, Koizume S, Miyagi E, et al. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer 2009; 101:2023.
  17. Colombo R, Gallipoli P, Castelli R. Thrombosis and hemostatic abnormalities in hematological malignancies. Clin Lymphoma Myeloma Leuk 2014; 14:441.
  18. Kakkar AK, Lemoine NR, Scully MF, et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82:1101.
  19. Hamada K, Kuratsu J, Saitoh Y, et al. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996; 77:1877.
  20. Zucchella M, Pacchiarini L, Tacconi F, et al. Different expression of procoagulant activity in human cancer cells cultured "in vitro" or in cells isolated from human tumor tissues. Thromb Haemost 1993; 69:335.
  21. Curatolo L, Alessio MG, Casali B, et al. Procoagulant activity of mouse transformed cells: different expression in freshly isolated or cultured cells. In Vitro Cell Dev Biol 1988; 24:1154.
  22. Koyama T, Hirosawa S, Kawamata N, et al. All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood 1994; 84:3001.
  23. Guarini A, Gugliotta L, Timoncini C, et al. Procoagulant cellular activity and disseminated intravascular coagulation in acute non-lymphoid leukaemia. Scand J Haematol 1985; 34:152.
  24. Wada H, Nagano T, Tomeoku M, et al. Coagulant and fibrinolytic activities in the leukemic cell lysates. Thromb Res 1983; 30:315.
  25. Guarini A, Gugliotta L, Valvassori L, et al. Human myeloid precursor cells do not possess or produce procoagulant activity (PCA). Exp Hematol 1986; 14:72.
  26. Falanga A, Consonni R, Marchetti M, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 1998; 92:143.
  27. Saito T, Koyama T, Nagata K, et al. Anticoagulant effects of retinoic acids on leukemia cells. Blood 1996; 87:657.
  28. Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995; 86:1072.
  29. Arbuthnot C, Wilde JT. Haemostatic problems in acute promyelocytic leukaemia. Blood Rev 2006; 20:289.
  30. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999; 96:2311.
  31. Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9:458.
  32. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197:1585.
  33. Chou J, Mackman N, Merrill-Skoloff G, et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104:3190.
  34. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005; 105:192.
  35. Tesselaar ME, Romijn FP, Van Der Linden IK, et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007; 5:520.
  36. Wang JG, Geddings JE, Aleman MM, et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012; 119:5543.
  37. Hron G, Kollars M, Weber H, et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97:119.
  38. Tesselaar ME, Romijn FP, van der Linden IK, et al. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 2009; 7:1421.
  39. Zahra S, Anderson JA, Stirling D, Ludlam CA. Microparticles, malignancy and thrombosis. Br J Haematol 2011; 152:688.
  40. Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15:6830.
  41. Gordon SG, Cross BA. A factor X-activating cysteine protease from malignant tissue. J Clin Invest 1981; 67:1665.
  42. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985; 24:5558.
  43. Gordon SG, Mielicki WP. Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis 1997; 8:73.
  44. Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res 1975; 6:127.
  45. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79:543.
  46. Donati MB, Gambacorti-Passerini C, Casali B, et al. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 1986; 46:6471.
  47. Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997; 78:759.
  48. André P, Hartwell D, Hrachovinová I, et al. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A 2000; 97:13835.
  49. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112:2703.
  50. Altieri DC, Edgington TS. The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor. J Biol Chem 1988; 263:7007.
  51. Edwards RL, Rickles FR. The role of leukocytes in the activation of blood coagulation. Semin Hematol 1992; 29:202.
  52. Edwards RL, Rickles FR, Bobrove AM. Mononuclear cell tissue factor: cell of origin and requirements for activation. Blood 1979; 54:359.
  53. Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988; 72:128.
  54. Gregory SA, Kornbluth RS, Helin H, et al. Monocyte procoagulant inducing factor: a lymphokine involved in the T cell-instructed monocyte procoagulant response to antigen. J Immunol 1986; 137:3231.
  55. Levy GA, Schwartz BS, Curtiss LK, Edgington TS. Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro. J Clin Invest 1981; 67:1614.
  56. Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Clin Med 1981; 98:917.
  57. Hara Y, Steiner M, Baldini MG. Characterization of the platelet-aggregating activity of tumor cells. Cancer Res 1980; 40:1217.
  58. Pearlstein E, Salk PL, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sci U S A 1980; 77:4336.
  59. Uchiyama T, Matsumoto M, Kobayashi N. Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy. Thromb Res 1990; 59:955.
  60. Sweeney JD, Killion KM, Pruet CF, Spaulding MB. von Willebrand factor in head and neck cancer. Cancer 1990; 66:2387.
  61. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002; 3:425.
  62. Bevilacqua MP, Pober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986; 83:4533.
  63. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163:740.
  64. Bauer KA, ten Cate H, Barzegar S, et al. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989; 74:165.
  65. Balkwill F, Osborne R, Burke F, et al. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 1987; 2:1229.
  66. Scuderi P, Sterling KE, Lam KS, et al. Raised serum levels of tumour necrosis factor in parasitic infections. Lancet 1986; 2:1364.
  67. Waage A, Espevik T, Lamvik J. Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol 1986; 24:739.
  68. Nickel KF, Ronquist G, Langer F, et al. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood 2015; 126:1379.
  69. Boccaccio C, Sabatino G, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434:396.
  70. Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 2013; 11:223.